Skip to main content
. Author manuscript; available in PMC: 2019 Apr 8.
Published in final edited form as: Nature. 2018 Oct 8;562(7727):434–438. doi: 10.1038/s41586-018-0603-3

Extended Data Fig. 8. Lgr5 is expressed in human vismodegib-persistent lesions.

Extended Data Fig. 8

(a) Table summarizing both the BCC and treatment characteristics in the patients analyzed. (b) Immunohistochemistry for K14 in biopsies before, after and during after vismodegib treatment. (c) In situ hybridization for LGR5 and GLI1 in biopsies from patients before, upon and after vismodegib treatment. (d) Percentage of tumour cells (Lgr5+ and Lgr5-) that express GLI1 in biopsies from patients, upon and after vismodegib Gli1 (n=3 samples from different patients (Patients 1-3) or body locations (Patient 4), total number of cells analysed indicated in parenthesis). Mean +/- s.e.m. (e-f) Immunohistochemistry for Ki67(e)and K10 (f) in biopsies before, during and during vismodegib treatment. Hoechst nuclear staining in blue; scale bars, 25 μm.